P
Patrick A. Robinson
Researcher at Boehringer Ingelheim
Publications - 64
Citations - 4698
Patrick A. Robinson is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Carotid endarterectomy & Nevirapine. The author has an hindex of 28, co-authored 64 publications receiving 4602 citations. Previous affiliations of Patrick A. Robinson include Oregon Health & Science University & Charleston Area Medical Center.
Papers
More filters
Journal ArticleDOI
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Julio S. G. Montaner,Peter Reiss,David K. C. Cooper,Stefano Vella,Marianne Harris,Brian Conway,Mark A. Wainberg,D. J. B. Smith,Patrick A. Robinson,David A. Hall,Maureen Myers,Joep M. A. Lange +11 more
TL;DR: In this paper, the authors compared the virologic effects of various combinations of nevirapine, didanosine, and zidovudine for sustained suppression of HIV-1 RNA.
Journal ArticleDOI
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
F. Van Leth,Praphan Phanuphak,Kiat Ruxrungtham,E Baraldi,S Miller,Brian Gazzard,Pedro Cahn,Umesh G. Lalloo,IP van der Westhuizen,Malan,Margaret Johnson,B R Santos,Fiona Mulcahy,Robin Wood,GC Levi,G Reboredo,Kathleen Squires,I Cassetti,D Petit,François Raffi,Christine Katlama,Robert L. Murphy,Andrej Horban,JP Dam,Elly A. M. Hassink,R. Van Leeuwen,Patrick A. Robinson,F. W. Wit,Lange Jm +28 more
TL;DR: Antiretroviral therapy with nevirapine or efavirenz showed similar efficacy, so triple-drug regimens with either NNRTI are valid for first-line treatment, there are, however, differences in safety profiles.
Journal ArticleDOI
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Dhayendre Moodley,Jagidesa Moodley,Hoosen M. Coovadia,Glenda E. Gray,James McIntyre,Justus Hofmyer,Cheryl Nikodem,David B. Hall,Maria Gigliotti,Patrick A. Robinson,Lynette Boshoff,South African Intrapartum Nevirapine Trial (Saint) Investigators +11 more
TL;DR: In this paper, the efficacy and safety of two inexpensive and easily deliverable antiretroviral (ARV) regimens for the prevention of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) type 1 during labor and delivery HIV-infected pregnant women were screened at 11 maternity health institutions in South Africa and were enrolled in an open-label short course ARV regimen of either nevirapine (Nvp) or multiple-dose zidovudine and lamivudine (Zdv/3TC
Journal ArticleDOI
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
Jerry O. Stern,Patrick A. Robinson,James Love,Stephan Lanes,Michael S. Imperiale,Douglas L. Mayers +5 more
TL;DR: Use of nevirapine was not associated with a significantly increased risk of clinical hepatotoxic events, including liver failure or liver related death, compared to therapy with other antiretroviral drugs.
Journal ArticleDOI
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
Janet Raboud,Julio S. G. Montaner,Brian Conway,S. Rae,Peter Reiss,Stephano Vella,David A. Cooper,Joep M. A. Lange,Marianne Harris,Mark A. Wainberg,Patrick A. Robinson,Maureen Myers,David A. Hall +12 more
TL;DR: The results demonstrate that suppression of pVL below 20 copies/ml is necessary to achieve a long-term antiretroviral response and support the need for a revision of current therapeutic guidelines for the management of HIV infection.